Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 401–500 of 1,000
Hosseini, S. S., Goudarzi, H., Ghalavand, Z., Hajikhani, B., Rafeieiatani, Z., & Hakemi-Vala, M. (2020) · Iranian Journal of Microbiology · doi:10.18502/ijm.v12i5.4603 · Cited by 44
In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?
Moore, J. D. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3468 · Cited by 50
Keegan, K. S., Li, C., Li, Z., Ma, J., Ragains, M. L., Coberly, S. K., Hollenback, D., Eksterowicz, J. E., Liang, L., Weidner, M. F., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0858 · Cited by 38
“CDK4 is a well-established cancer drug target for a broad spectrum of RB-positive cancers (23, 24).”
BackgroundBassey-Archibong, B. I., Kwiecień, J. M., Milosavljevic, S., Hallett, R. M., Rayner, L., Erb, M. J., Crawford-Brown, C., Stephenson, K. B., Pa, B., Hassell, J. A., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.17 · Cited by 49
El‐Ashmawy, N. E., Khedr, N. F., El‐Bahrawy, H. A., & Mansour, H. E. A. (2017) · Tumor Biology · doi:10.1177/1010428317692235 · Cited by 40
Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2
Witt, D., Burfeind, P., Hardenberg, S. V., Opitz, L., Salinas, G., Bremmer, F., Schweyer, S., Thelen, P., Neesen, J., & Kaulfuß, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt019 · Cited by 37
The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells
Badía, R., Pujantell, M., Riveira‐Muñoz, E., Puig, T., Torres‐Torronteras, J., Martí, R., Clotet, B., Ampudia, R. M., Vives‐Pi, M., Esté, J. A., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005829 · Cited by 39
“The following antibodies were used for immunoblotting: anti-rabbit and anti-mouse horseradish peroxidase-conjugated secondary antibodies (1:5000; Pierce); anti-human Hsp90 (1:1000; 610418, BD Biosciences), anti-SAMHD1 (1:1000; ab67820, Abcam), anti-CDK1 (9116) anti-CDK2 (2546), anti-phosphoCDK2 (Thr160; 2561), anti-CD…”
BackgroundInfluentialThe pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2
Watanabe, M., Iizumi, Y., Sukeno, M., Iizuka-Ohashi, M., Sowa, Y., & Sakai, T. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.10 · Cited by 38
Allosteric Modulators of Protein–Protein Interactions (PPIs)
Ni, D., Liu, N., & Sheng, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_13 · Cited by 38
Wang, Q., Yang, Y., Fu, X., Wang, Z., Liu, Y., Li, M., Zhang, Y., Li, Y., Li, P., Yu, T., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.018 · Cited by 37
Jardim, D. L. F., Millis, S. Z., Ross, J. S., Woo, M. S.-A., Ali, S. M., & Kurzrock, R. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0509 · Cited by 39
LncRNA ADAMTS9-AS1, as prognostic marker, promotes cell proliferation and EMT in colorectal cancer
Chen, W., Tu, Q., Yu, L., Xu, Y., Yu, G., Jia, B., Cheng, Y., & Wang, Y. (2020) · Human Cell · doi:10.1007/s13577-020-00388-w · Cited by 37
Jeong, K., Murphy, J. M., Ahn, E.-Y. E., & Lim, S. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab132 · Cited by 38
“However, CDK inhibitors (CDKIs)—Ink4 families for CDK 4/6 and Cip/ Kip families for CDK 4/6 and 2—can inactivate cyclin-bound CDKs, which adds to the complexity of cell cycle regulation.(14,15) As such, both activation of cyclin–CDK complexes and repression of CDKIs are required to properly operate G1-to-S cell cycle…”
BackgroundUSP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1
Li, G. L., Yang, T., Chen, Y., Bao, J., Wu, D., Hu, X., Feng, C., Xu, L., Li, M., Li, G., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720307 · Cited by 37
“USP5 Knockdown Decreased CyclinD1 Protein Stability The above studies showed that GBM cells were arrested in cell cycle G1 phase after USP5 knockdown, so we wondered whether USP5 regulated key proteins driving cell cycle G1 to S transition, including CDK2, CDK4, CDK6, CyclinD1, and CyclinE1 (Malumbres and Barbacid, 20…”
BackgroundInfluentialBiophysical Survey of Small-Molecule β-Catenin Inhibitors: A Cautionary Tale
McCoy, M. A., Spicer, D., Wells, N. J., Hoogewijs, K., Fiedler, M., & Baud, M. G. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00228 · Cited by 40
Degradation strategy of cyclin D1 in cancer cells and the potential clinical application
Chen, S., & Li, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949688 · Cited by 47
“Nevertheless, cyclin D1, cyclin D2, and cyclin D3 have similar phosphorylation sites for FBX4 binding (Thr286, Thr280, and Thr283) (3).”
BackgroundInfluentialPotential roles of longan flower and seed extracts for anti-cancer
Lin, C. (2012) · World Journal of Experimental Medicine · doi:10.5493/wjem.v2.i4.78 · Cited by 37
Ye, P., Shen, L., Jiang, W., Ye, Y., Chen, C. A., Wu, X., Wang, K., & Wu, B. (2014) · Marine Drugs · doi:10.3390/md12063203 · Cited by 37
Bizen, N., Inoue, T., Shimizu, T., Tabu, K., Kagawa, T., & Taga, T. (2013) · Stem Cells · doi:10.1002/stem.1613 · Cited by 41
Song, N. R., Lee, E.-J., Byun, S., Kim, J., Mottamal, M., Park, J. H. Y., Lim, S. S., Bode, A. M., Lee, H. J., Lee, K. W., et al. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0134 · Cited by 37
“Abundant evidence indicates that cell-cycle deregulation plays a crucial role in several types of human cancer (17, 37).”
BackgroundAdvances in sarcoma gene mutations and therapeutic targets
Gao, P., Seebacher, N. A., Hornicek, F. J., Guo, Z., & Duan, Z. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.001 · Cited by 38
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer
Lim, J. S. J., Turner, N. C., & Yap, T. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0563 · Cited by 38
Liang, Y., Feng, Y., Zong, M., Wei, X., Lee, J., Feng, Y., Li, H., Yang, G., Wu, Z., Fu, X., et al. (2018) · Hepatology · doi:10.1002/hep.29661 · Cited by 36
“(32) cyclin D1 expression was lower in ctnnb1 hep-/than WT livers at early time points after plasmid injection as described above (Fig.”
BackgroundWang, S., Li, C., Zhang, L., Chen, Q., & Wang, S. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117901 · Cited by 36
Priyadarsini, R. V., Kumar, N., Khan, I., Thiyagarajan, P., Kondaiah, P., & Nagini, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034628 · Cited by 36
“Downregulation of cyclin D1 by dietary supplementation of chlorophyllin and ellagic acid may be attributed to abrogation of signaling through receptor tyrosine kinases, and the MEK–ERK, WNT, and NF-kB pathways as well as TGF-b mediated antiproliferative control [34].”
BackgroundWang, Y., Zheng, Z., Zhang, J., Wang, Y., Kong, R., Liu, J., Zhang, Y., Deng, H., Du, X., & Ke, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655597 · Cited by 39
Huth, H. W., Albarnaz, J. D., Torres, A. A., Bonjardim, C. A., & Ropert, C. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.05.009 · Cited by 37
Chen, H., Xu, X., Wang, G., Zhang, B., Wang, G., Xin, G., Liu, J., Jiang, Q., Zhang, H., & Zhang, C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.773226 · Cited by 39
Fulvestrant for the treatment of advanced breast cancer
Blackburn, S. A., Parks, R. M., & Cheung, K. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1473038 · Cited by 39
“Inhibitors target proteins controlling mitochondrial function, cell growth, adhesion, and motility [51].”
BackgroundLaphanuwat, P., Likasitwatanakul, P., Sittithumcharee, G., Thaphaengphan, A., Chomanee, N., Suppramote, O., Ketaroonrut, N., Charngkaew, K., Lam, E. W. ‐., Okada, S., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.214726 · Cited by 43
Cheng, Y., Pan, Y., Pan, Y., & Wang, O. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188007 · Cited by 42
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients
Tao, Z., Li, T., Feng, Z., Liu, C., Shao, Y., Zhu, M., Gong, C., Wang, B., Cao, J., Wang, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01023 · Cited by 39
“CCND1 amplification is commonly mutated in various solid tumors and should be highly sensitive to cyclindependent kinase (CDK) 4/6 inhibition (24).”
BackgroundKhodabakhsh, F., Bourbour, M., Yaraki, M. T., Bazzazan, S., Bakhshandeh, H., Cohan, R. A., & Tan, Y. N. (2022) · Molecules · doi:10.3390/molecules27175418 · Cited by 38
“Among the cyclin family, isoform D1 has been shown to be significantly associated with gastric cancer, and its overexpression leads to cancerous responses and weakness in patients [59].”
BackgroundPrognostic Potential of Cyclin D1 Expression in Colorectal Cancer
Jun, S., Kim, J., Yoon, N., Maeng, L.-S., & Byun, J. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020572 · Cited by 40
“including pancreatic ductal adenocarcinoma, non-small cell lung cancer (NSCLC), and melanoma, frequently show cyclin D1 overexpression and amplification, which emphasizes the potential use of CDK4/6 inhibitors in their treatment [9,10].”
BackgroundCo-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 39
Sharma, A. K., Madhunapantula, S. V., Gowda, R., Berg, A. S., Neves, R. I., & Robertson, G. P. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.019 · Cited by 38
Neumann, J., Boerries, M., Köhler, R., Giaisi, M., Krammer, P. H., Busch, H. S., & Li‐Weber, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28521 · Cited by 40
“Typically, CDK4 and CDK6 that are crucial for G1 checkpoint control are often over-expressed in many malignancies.(2,3) Evidence shows that deregulation of CDK4 and CDK6 activity is associated with a wide variety of tumors.”
BackgroundPRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1
Schneider, L., Herkt, S. C., Wang, L., Feld, C., Wesely, J., Kuvardina, O. N., Meyer, A., Oellerich, T., Häupl, B., Seifried, E., et al. (2021) · Oncogenesis · doi:10.1038/s41389-021-00332-z · Cited by 37
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy
Migliaccio, I., Leo, A. D., & Malorni, L. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000129 · Cited by 35
“D-type cyclins are fundamental regulators of cell cycle entry and function by binding preferentially to cyclin-dependent kinases 4 and 6 (CDK4/6) [2,3].”
BackgroundPathoor, R., & Bahulayan, D. (2018) · New Journal of Chemistry · doi:10.1039/c8nj00032h · Cited by 35
Kwon, N. H., Lee, J. Y., Ryu, Y.-L., Kim, C., Kong, J., Oh, S., Kang, B. S., Ahn, H. W., Ahn, S. G., Jeong, J., et al. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00001 · Cited by 37
Farghadani, R., Seifaddinipour, M., Rajarajeswaran, J., Abdulla, M. A., Hashim, N. M., Khaing, S. L., & Salehen, N. B. (2019) · PeerJ · doi:10.7717/peerj.7686 · Cited by 37
“Therefore, induction of cell cycle arrest through up-regulation of CDKIs to re-sensitize cancer cells and down-regulation of cyclins and cyclin-dependent kinases (CDKs) is an important mechanism of cancer therapeutic agents in breast cancer cells (Musgrove et al., 2011; Parveen et al., 2016).”
BackgroundSalla, M., Pandya, V., Bhullar, K. S., Kerek, E. M., Wong, Y. F., Losch, R., Ou, J., Aldawsari, F. S., Velázquez‐Martínez, C. A., Thiesen, A., et al. (2020) · Molecules · doi:10.3390/molecules25173849 · Cited by 36
“Several reports have shown that Cdk4 hyperactivity is associated with the overexpression of cyclin D [37] and several cancers showing elevated levels of cyclin D1 expression including breast (60% of patients), CRC (40% of patients), and prostate cancers (20% of patients) [38].”
BackgroundTargeted Therapies for Epstein-Barr Virus-Associated Lymphomas
Pei, Y., Wong, J. H.-Y., & Robertson, E. S. (2020) · Cancers · doi:10.3390/cancers12092565 · Cited by 37
“Cyclin D and cyclin-dependent kinase (CDK) have been identified as potential therapeutic targets in cancers [19].”
BackgroundTanaka, Y., Murata, M., Oda, Y., Furue, M., & Ito, T. (2021) · Biomedicines · doi:10.3390/biomedicines9040355 · Cited by 35
“Cyclin D1 is frequently overexpressed and/or amplified in many types of cancers, including cSCC [40,45,46].”
BackgroundChaudhary, S., Pothuraju, R., Rachagani, S., Siddiqui, J. A., Atri, P., Mallya, K. B., Nasser, M. W., Sayed, Z., Lyden, E. R., Smith, L. M., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.004 · Cited by 36
Kasomva, K., Savarimuthu Ignacimuthu, S. J., & Paulraj, M. G. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.09.022 · Cited by 38
Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells
Bassey-Archibong, B. I., Rayner, L. G. A., Hercules, S. M., Aarts, C. W., Dvorkin‐Gheva, A., Bramson, J. L., Hassell, J. A., & Daniel, J. M. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.92 · Cited by 35
Park, G. H., Song, H. M., Park, S. B., Son, H.-J., Um, Y., Kim, H., & Jeong, J. B. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2096-x · Cited by 36
“Because cyclin D1 protein level is regulated by gene amplification [16], we investigated whether TC-HW affects cyclin D1 transcription.”
BackgroundInfluentialCell cycle-related kinase in carcinogenesis
Tian, Y., WAN, H., & Tan, G. (2012) · Oncology Letters · doi:10.3892/ol.2012.828 · Cited by 39
“Thus, abnormally high levels of cyclin D1 are involved in a number of GI and non-GI malignancies, including those originating from the oral cavity, esophagus, breast and bladder (65-67).”
Cooperation between Dmp1 Loss and Cyclin D1 Overexpression in Breast Cancer
Zhu, S., Mott, R. T., Fry, E. A., Taneja, P., Kulik, G., Sui, G., & Inoue, K. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.06.027 · Cited by 34
“Overall, these studies suggested that cyclin D1 regulates cell proliferation, growth, and differentiation, and its transcriptional regulatory activity has great potential significance in human cancer progression.(5,11) Among known cyclin D1eassociated transcriptional factors, cyclin Deinteracting Myb-like Protein 1 (D…”
BackgroundAlves, M. R., Melo, N. C. E., Barros‐Filho, M. C., do Amaral, N. S., Ilelis, F., Baiocchi, G., Soares, F. A., Brot, L. D., & Rocha, R. M. (2018) · Cancer Medicine · doi:10.1002/cam4.1530 · Cited by 34
Ha, S., Zhu, J., Xiang, H., & Luo, G. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109192 · Cited by 37
Expression of cyclin d1 and its association with disease characteristics in bladder cancer.
Kopparapu, P. K., Boorjian, S. A., Robinson, B. D., Downes, M., Gudas, L. J., Mongan, N. P., & Persson, J. L. (2013) · PubMed · Cited by 34
Colorectal cancer drug target prediction using ontology-based inference and network analysis
Tao, C., Sun, J., Zheng, W. J., Chen, J., & Xu, H. (2015) · Database · doi:10.1093/database/bav015 · Cited by 34
“Therefore, it might be a promising anti-cancer therapeutic target (38).”
BackgroundThe role of cyclin D1 in response to long-term exposure to ionizing radiation
Shimura, T., Fukumoto, M., & Kunugita, N. (2013) · Cell Cycle · doi:10.4161/cc.25746 · Cited by 38
“Cyclin D1 is considered a potential therapeutic target for cancer treatment.(58,59) Aberrant cyclin D1 expression is often detected in premalignant and malignant tissues.”
BackgroundChiabotto, G., Bruno, S., Collino, F., & Camussi, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159163 · Cited by 34
“CCND1 encodes a regulatory subunit of the cyclin-dependent kinase 4 (CDK4) and of the cyclin-dependent kinase 6 (CDK6), whose activity is required for cell cycle G1/S transition [79].”
BackgroundMa, J., Ren, Y., Zhang, L., Kong, X., Wang, T., Shi, Y., & Bu, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174309 · Cited by 33
CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis
Birnhuber, A., Egemnazarov, B., Biasin, V., Rad, E. B., Wygrecka, M., Olschewski, H., Kwapiszewska, G., & Marsh, L. M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01433-w · Cited by 33
Kolapalli, S. P., Sahu, R., Chauhan, N. R., Jena, K. K., Mehto, S., Das, S. K., Jain, A., Rout, M., Dash, R., Swain, R. K., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1871 · Cited by 35
“DZIP3 interacts at 30UTR of Cyclin D1 mRNA and stabilizes it The aberrant overexpression of Cyclin D1 is strongly associated with the pathogenesis and progression of several cancer types (46).”
Backgroundvan Harten, A. M., & Brakenhoff, R. H. (2021) · Cancers · doi:10.3390/cancers13112774 · Cited by 38
“ent chromatin modification pathways (as reviewed i [172]).”
BackgroundNew Therapeutic Strategies for Adult Acute Myeloid Leukemia
Ishii, H., & Yano, S. (2022) · Cancers · doi:10.3390/cancers14112806 · Cited by 37
Hu, G., Yang, T., Zheng, J., Dai, J., Nan, A., Lai, Y., Zhang, Y., Yang, C., & Jiang, Y. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22314 · Cited by 34
Proinflammatory Homeobox Gene, ISX , Regulates Tumor Growth and Survival in Hepatocellular Carcinoma
Hsu, S., Wang, L., Lee, K.-T., Chen, Y.-L., Liu, K.-Y., Suen, J., Chai, C., & Wang, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2795 · Cited by 35
“Isx, a gut-specific transcription factor, was a putative repressor for intestinal SRBI and BCMO1 expression that consequently repressed vitamin A production and downstream retinoic acid (RA) signaling (3, 14).”
BackgroundResultInfluentialRole of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis
Bhattacharjee, S., Roy, S. G., Bose, P., & Saha, A. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00457 · Cited by 33
“…| www.frontiersin.org 8 April 2016 | Volume 7 | Article 457 with reduced proteolytic activity and inhibited GSK-3β kinasing function which phosphorylates at T286 cyclin D1 leading to cycltoplasmic localization for ubiquitin-proteasome mediated degradation (Alao, 2007; Musgrove et al., 2011).”
BackgroundO'Sullivan, C. C. (2015) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/2/4/1029 · Cited by 35
“Phosphorylation and inactivation of Rb causes dissociation of E2F transcription factors and transcriptional regulation of genes which play an important role in facilitating G1-S phase transition, DNA replication, DNA repair and mitosis [19-24].”
An Overview of Molecular Cancer Pathogenesis, Prognosis, and Diagnosis
Cullen, J. M., & Breen, M. (2016) · Wiley eBooks · doi:10.1002/9781119181200.ch1 · Cited by 50
Alikarami, F., Safa, M., Faranoush, M., Hayat, P., & Kazemi, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.022 · Cited by 33
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Han, X., Li, J., Wang, W., Cui, Y., & Li, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.007 · Cited by 32
Zhong, Q., Hu, Z., Li, Q., Yi, T., Li, J., & Yang, H. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.027 · Cited by 35
Anti‐tumor platinum (IV) complexes bearing the anti‐inflammatory drug naproxen in the axial position
Tolan, D. A., Abdel-Monem, Y. K., & El‐Nagar, M. A. (2019) · Applied Organometallic Chemistry · doi:10.1002/aoc.4763 · Cited by 32
Cheng, X., Wang, X., Wu, Z., Tan, S. H., Zhu, T., & Ding, K. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12639 · Cited by 32
Chang, W. H., & Lai, A. G. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.008 · Cited by 32
Fan, H., Zhu, M.-Y., Peng, S., Zhu, J., Zhang, J., & Qu, G.-Q. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152795 · Cited by 33
Tiemin, P., Xiao, P., Qingfu, L., Wang, Y., Junlin, X., Zhefeng, H., Ming, Z., Desen, L., & Qinghui, M. (2020) · Oncogenesis · doi:10.1038/s41389-020-0207-2 · Cited by 32
Huang, C., Liang, J., Lin, S., Wang, D., Xie, Q., Lin, Z., & Yao, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666597 · Cited by 32
“CyclinD1 (CCND1) was a vital gene among the 64 predicted target genes given previous studies alluding to its importance in cervical cancer development (19, 20).”
BackgroundPES1 differentially regulates the expression of ERα and ERβ in ovarian cancer
Li, J., Zhuang, Q., Lan, X., Zeng, G., Jiang, X., & Huang, Z. (2013) · IUBMB Life · doi:10.1002/iub.1228 · Cited by 32
“The overexpression of cyclin D1, the major regulatory subunit for CDK4, is common in human cancers with an epithelial cell origin (55).”
BackgroundJiang, K., Yang, Z., Cheng, L., Wang, S., Ning, K., Zhou, L., Lin, J., Zhong, H., Wang, L., Yang, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467837 · Cited by 39
Stoeckius, M., Erat, A., Fujikawa, T., Hiromura, M., Koulova, A., Otterbein, L. E., Bianchi, C. F., Tobiasch, E., Dagon, Y., Sellke, F. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.266510 · Cited by 32
A CULLINary ride across the secretory pathway: more than just secretion
Lu, A., & Pfeffer, S. R. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.02.001 · Cited by 33
“Depletion of RhoBTB2 results in elevated Cyclin D levels [58], a phenotype frequently observed in cancer [59].”
BackgroundShimura, T. (2016) · International Journal of Radiation Biology · doi:10.1080/09553002.2016.1257832 · Cited by 32
“The currently feasible clinical approaches to inhibiting cyclin D1 function are carried out by using inhibitor of CDK4/CDK6 (Musgrove et al. 2011).”
BackgroundWang, H., Zhang, X., Vidaurre, I., Cai, R., Sha, W., & Schally, A. V. (2018) · International Journal of Cancer · doi:10.1002/ijc.31308 · Cited by 33
“Overexpression of cyclin D is also considered as a consequence of oncogenic activation of mitogenic signaling pathways including RAS-MEK-ERK and PI3K/AKT pathways.(37,38) Both cyclin D and CDK4/6 are therapeutic targets in cancer treatment.”
BackgroundThe differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing
Mas, A., Alonso, R., Garrido‐Gómez, T., Escorcia, P., Montero, B., Jimenez-Almazán, J., Martín, J., Pellicer, N., Monleón, J., & Simón, C. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.05.018 · Cited by 32
Rattanaburee, T., Thongpanchang, T., Wongma, K., Tedasen, A., Sukpondma, Y., & Graidist, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109115 · Cited by 32
Thyroid hormone actions in liver cancer
Wu, S., Cheng, W., Lin, C. D., & Lin, K. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1146-7 · Cited by 35
“Cyclin D1 is an important regulator at the G1 to S phases of cell cycle progression, and its overexpression leads to increased cyclin-dependent kinase 4/6 (CDK4/6) activity, retinoblastoma protein (pRb) phosphorylation, activation of E2F–responsive genes, and consequent increased proliferation [64].”
BackgroundShay, J. W., Homma, N., Zhou, R., Naseer, M. I., Chaudhary, A. G., Al-Qahtani, M., Hirokawa, N., Goudarzi, M., Fornace, A. J., Baeesa, S. S., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-2858-0 · Cited by 37
Jia, Y., Du, J., Chen, X., Nie, R.-C., Hu, G.-S., Wang, L., Zhang, Y., Chen, S., Wen, X.-S., Luo, D., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2420383122 · Cited by 37
“CCND1 has been shown to be a critical downstream target gene of estrogen/ER - induced cell cycle progression and cell growth in ER - positive breast cancer ( 61 , 72 – 74 ).”
Li, L., Wei, X., Wu, B., Xiao, Y., Yin, M., & Yang, Q. (2017) · Oncology Letters · doi:10.3892/ol.2017.5828 · Cited by 31
“Cyclin D1 is known to be the primary cyclin that couples to cyclin-dependent kinases 4/6 and drives G 1 to S phase cell cycle progression (30), therefore cyclin D1 protein expression was evaluated using western blotting.”
Cell Cycle Regulation in Treatment of Breast Cancer
Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 37
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
Nabavi, N., Bennewith, K. L., Churg, A., Wang, Y. Z., Collins, C. C., & Mutti, L. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.124 · Cited by 32
“com/Genes&Cancer pleural mesotheliomas such as BAP1 [67], NF2 [71], LATS1,2 [63, 72-74], PBRM1 [67], TP53 [75-77], AURKA [78], CDKN2A [79], RB1 [80], BRCA2 [81], CCND1 [82], SETD2 [83], SMARCC1 [67] or PCNA [84] are also found in other cancer types.”
Alsereihi, R., Schulten, H.-J., Bakhashab, S., Saini, K. S., Al-Hejin, A. M., & Hussein, D. M. (2019) · Cancers · doi:10.3390/cancers11070890 · Cited by 35
“The CCND1 cyclin was shown to be required for the cell cycle G1/S transition, and associated gene overexpression has been observed frequently in a variety of tumors [124].”
BackgroundEl‐Daly, S. M., Gamal‐Eldeen, A. M., Gouhar, S. A., Abo-Elfadl, M. T., & El-Saeed, G. S. M. (2020) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-020-03378-8 · Cited by 32
Brighi, N., Conteduca, V., Lolli, C., Gurioli, G., Schepisi, G., Palleschi, M., Mariotti, M., Casadei, C., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103199 · Cited by 33
Su, H., Fan, G., Huang, J., & Qiu, X. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110049 · Cited by 31
RetractedLi, D., Yu, Q., Zeng, C.-X., Ye, L.-X., Guo, Y., Liu, J.-F., Zheng, H.-H., Feng, D., & Wei, W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1096491 · Cited by 35
“Cyclin D1 (CCND1), as a protein encoding gene, is highly expressed in KIRC and can promote KIRC cell proliferation by regulating the cell cycle (Musgrove et al., 2011; Patel et al., 2022).”
BackgroundAndrew, A. S., Gui, J., Hu, T., Wyszynski, A., Marsit, C. J., Kelsey, K. T., Schned, A. R., Tanyos, S. A., Pendleton, E. M., Ekstrom, R. M., et al. (2014) · British Journal of Urology · doi:10.1111/bju.12641 · Cited by 31
Leung, H.-W., Zhao, S., Yue, G. G., Lee, J. K.-M., Fung, K., Leung, P., Tan, N., & Lau, C. B. (2015) · Scientific Reports · doi:10.1038/srep16985 · Cited by 31
17β-Estradiol promotes endometrial cancer proliferation and invasion through IL-6 pathway
Che, Q., Xiao, X., Xu, J., Liu, M., Lu, Y., Liu, S., & Dong, X. (2019) · Endocrine Connections · doi:10.1530/ec-19-0258 · Cited by 34
Russo, L. C., de Araujo, C. B., Iwai, L. K., Ferro, E. S., & Forti, F. L. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.06.028 · Cited by 30
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.